Cancer Letters
Volume 228, Issue 1 , Pages 91-96 , 18 October 2005

Protein chip array profiling analysis of sera from neuroblastoma patients

Received 26 November 2004 ,Accepted 2 December 2004.

References 

  1. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  2. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609–3614
  3. Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 2002;94:1576–1578
  4. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 2002;48:1296–1304
  5. Thiesse P, Hany MA, Combaret V, Ranchère-Vince D, Bouffet E, Bergeron C. Assessment of percutaneous fine needle aspiration cytology as a technique to provide diagnostic and prognostic information in neuroblastoma. Eur. J. Cancer. 2000;36:1544–1551
  6. Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith EI, Altshuler G, et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am. J. Clin. Oncol. 1992;15:295–303
  7. Zeltzer PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer. 1986;57:1230–1234
  8. Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Children Cancer Study Group experience. Cancer Res. 1985;45:2843–2848
  9. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004;10:43–52
  10. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, et al. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer. 2001;92:2072–2075
  11. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003;3:1720–1724
  12. Glojnaric I, Casl MT, Simic D, Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin. Chem. Lab. Med. 2001;39:129–133
  13. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest. 2004;84:845–856
  14. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis, amyloid, Int. J. Exp. Clin. Invest. 1994;1:119–137
  15. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2000;21:1164–1177
  16. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell Proteomics. 2004;3:367–378

PII: S0304-3835(05)00321-6

doi: 10.1016/j.canlet.2004.12.053

Cancer Letters
Volume 228, Issue 1 , Pages 91-96 , 18 October 2005

Article Tools

* Image Usage & Resolution